HC Wainwright Rates Nuvectis Pharma (NVCT) buy, $13 Price Target
HC Wainwright maintains a Buy rating on Nuvectis Pharma with a target price of $13.0, as shares trade at $10.72, a 21.21% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Nuvectis Pharma, Inc. ($NVCT) "buy" with a $13 price target on June 12, 2026.
Since the rating, $NVCT is up 54.3% after 1 week, up 72.2% after 1 month and up 73.7% to date (from the $10.71 close on Jun 12, 2026).
NVCT
Nuvectis Pharma, Inc.
Key Points
- On June 12, 2026, HC Wainwright reiterated its Buy rating on Nuvectis Pharma, Inc. (NVCT) with a price target of $13.0.
- After the reiteration, NVCT shares closed at $10.72, reflecting a significant gap to the target price, suggesting potential upside.
- With a market cap of about $717.5 million, Nuvectis specializes in developing precision medicines for oncology.
Get $NVCT trade alerts by text
We text you when insiders, Congress or big funds trade $NVCT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Nuvectis Pharma, Inc. alert may contain errors. Disclosures
HC Wainwright's Reiteration
On June 12, 2026, HC Wainwright reiterated its Buy rating on Nuvectis Pharma, Inc. (NASDAQ: NVCT), setting a target price of $13.0. The stock closed at $10.72 following this announcement. This reiteration signals continued confidence in the stock despite its current trading price well below the target.
Analysts Set New Price Targets
HC Wainwright's recent call aligns with a broader positive sentiment from other analysts. On June 22, 2026, the firm maintained its Buy rating on NVCT with an earlier target of $39.0. Roth Capital also showed support by maintaining its Buy rating on July 6, 2026, while raising its target to $33.0 from $20.0. Meanwhile, Cantor Fitzgerald initiated coverage with an Overweight rating on August 24, 2026. These ratings reflect a general belief in Nuvectis as a promising opportunity within the biotechnology sector.
Stock Performance Insight
Currently, NVCT shares are trading significantly lower than their 52-week high of $29.27. The stock has seen volatility, with a low of $5.55 over the past year. This performance is noteworthy, especially as analysts speculate on the company's prospects resulting from its clinical trials. The recent price of $10.72 positions the stock well below its potential target estimates, suggesting a perceived undervaluation by analysts.
$NVCT price target
Nuvectis Pharma, Inc. daily closes and this analyst's $13 target. Not advice.
Recent Insider Activity
Insider activity at Nuvectis Pharma shows strong confidence from key executives. On June 30, 2026, Mosseri Marlio Charles bought 50,000 shares at an average price of $18.32, totaling around $916,000. Additionally, Chairman and CEO Ron Bentsur acquired 12,500 shares at $20.00, valued at approximately $250,000. These transactions reflect the insiders' belief in the company's future, especially as they come amid ongoing developments in drug trials.
What NVCT Does
Nuvectis Pharma, Inc. is focused on developing innovative treatments for oncology, with its lead candidate NXP900 currently in a Phase 1b clinical trial. As a clinical-stage biopharmaceutical firm based in Fort Lee, New Jersey, Nuvectis aims to address serious medical needs in cancer care, driving interest from investors and analysts alike.
What's Ahead for NVCT
Investors will be keen to watch Nuvectis Pharma's next earnings report, scheduled for November 3, 2026. As the company continues its clinical trials and potential new data emerges, further analyst coverage and insider activity will be essential to monitor. Remember, the latest analyst ratings reflect past evaluations of the company's prospects and may change as new information becomes available.
Related Filing Alerts
Source: HC Wainwright's rating change on $NVCT (Jun 12, 2026). Written by software, not financial advice. How we make alerts